[
    [
        {
            "time": "",
            "original_text": "【民生医药|周报】外包行业3/9：持续推荐CXO板块具备α属性的公司",
            "features": {
                "keywords": [
                    "民生医药",
                    "外包行业",
                    "CXO板块",
                    "α属性"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CXO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【民生医药|周报】外包行业3/9：持续推荐CXO板块具备α属性的公司",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "国内医药CRO行业高速发展，具备技术优势企业或迎更大红利",
            "features": {
                "keywords": [
                    "国内医药",
                    "CRO行业",
                    "高速发展",
                    "技术优势",
                    "红利"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "CRO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国内医药CRO行业高速发展，具备技术优势企业或迎更大红利",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【医药-马帅】从商业模式深度剖析药明康德：坚守高水平CRO服务，新药研发产业链航母再起航",
            "features": {
                "keywords": [
                    "药明康德",
                    "商业模式",
                    "CRO服务",
                    "新药研发",
                    "产业链"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CRO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【医药-马帅】从商业模式深度剖析药明康德：坚守高水平CRO服务，新药研发产业链航母再起航",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]